First-Line, Fixed-Duration Nivolumab Plus Ipilimumab Followed by Nivolumab in Clinically Diverse Patient Populations With Unresectable Stage III or IV Melanoma: CheckMate 401 Patients who underwent ...

According to a new analysis, PLND does not impact recurrence-free survival but may reduce metastatic spread in intermediate- and high-risk prostate cancer. The benefit of PLND is most evident in ...

Recently, omission of axillary lymph node dissection among patients with early breast cancer has been found to have no detrimental effect on outcomes in most cases, continuing a trend toward less ...

Please provide your email address to receive an email when new articles are posted on . More than 40% of patients with lymph node involvement at breast cancer diagnosis could be spared lymph node ...

Study finds lower mortality rates associated with excisions of higher numbers of lymph nodes in patients with intermediate- and high-risk prostate cancer. Removal of greater numbers of lymph nodes ...

Breakthrough research presented at the 2026 Society of Thoracic Surgeons Annual Meeting shows that additional lymph node evaluation is needed during surgery for non-small cell lung cancer (NSCLC) to ...

Nivolumab and Ipilimumab for Metastatic Castration-Resistant Prostate Cancer With an Immunogenic Signature: The Multicenter, Two-Cohort, Phase II NEPTUNES Study We conducted a multicenter, open-label, ...

Patients with clinically node-negative breast cancer after neoadjuvant chemotherapy demonstrated low axillary and locoregional recurrence rates after sentinel lymph node biopsy (SLNB) or targeted ...

Adequate lymph node yield for patients with papillary thyroid cancer is associated with longer operations, longer hospitalization, and higher risk of recurrent laryngeal nerve injury and hypocalcemia, ...